Patient reported outcomes and health related quality of life in localized prostate cancer: A review of current evidence.

Oncological outcomes after localized prostate cancer (CaP) treatment are excellent and generally considered equivalent across treatment modalities. Thus, short, and long-term patient health related quality of life (HRQoL) is an important factor in treatment discussions. The purpose of this review was to assess the impact of treatment modality for localized CaP on HRQoL as reflected by recent published trials.

We conducted a literature review using the PubMed database for studies published between January 2010 and January 2021. We included randomized control trials and observational cohort studies examining HRQoL in patients with localized CaP treated with active surveillance, radical prostatectomy, external beam radiotherapy or brachytherapy.

Four randomized control trials and 15 prospective cohort studies were reviewed. Current evidence suggests that surgery has the largest short and long-term negative effect on sexual function and incontinence but advantages with regards to bowel function and irritative-obstructive urinary symptoms. Radiation therapy mainly impacts urinary irritative symptoms and bowel bother. Short-term HRQoL outcomes for active surveillance are most favorable, however, during long-term follow up, there is no significant difference in comparison to radiation. Long-term global quality of life impact regarding anxiety, mental, emotional well-being, and fatigue seem to be equivalent between treatment modalities.

The choice of primary treatment modality for localized CaP results in a unique impact profile on cancer specific HRQoL in both the short and long-term periods. Understanding the different adverse events profiles can provide a basis for informing patients and clinicians regarding the impact of disease and treatments on quality of life and allow for a better patient centered discussion.

Urologic oncology. 2022 May 23 [Epub ahead of print]

Eyal Kord, John Paul Flores, Natasza Posielski, Hannah Koenig, On Ho, Christopher Porter

Section of Urology and Renal Transplantation, Virginia Mason Hospital and Seattle Medical Center, Seattle, WA. Electronic address: ., Department of Hematology and Oncology, Virginia Mason Hospital and Seattle Medical Center, Seattle, WA., Section of Urology and Renal Transplantation, Virginia Mason Hospital and Seattle Medical Center, Seattle, WA.

email news signup